# Three Dosing Schedules of Oral Rigosertib in MDS Patients

> **NCT02075034** · PHASE1 · WITHDRAWN · sponsor: **Traws Pharma, Inc.**

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** rigosertib

## Key facts

- **NCT ID:** NCT02075034
- **Lead sponsor:** Traws Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-05
- **Primary completion:** 2019-08
- **Final completion:** 2019-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2020-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02075034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02075034, "Three Dosing Schedules of Oral Rigosertib in MDS Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02075034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*